Jonathan Wall, PhD, Professor and Director of the University of Tennessee Graduate School of Medicine’s Amyloidosis and Cancer Theranostics Program and Co-founder & Interim Chief Scientific Officer at Attralus, gives an overview of immunoglobulin light chain-associated (AL) amyloidosis.
As Dr. Wall explains, AL amyloidosis is a rare blood disorder associated with the overproduction of amyloid, which leads to the deterioration of vital organs, most notably the heart, kidneys, and liver. The heterogeneity of this disease makes it difficult to diagnose and treat. There is no genetic predisposition for AL amyloidosis nor are there specific environmental factors associated with the disease.
To learn more about AL amyloidosis and other rare blood disorders, visit checkrare.com/diseases/hematologic-disorders/.
